01- ECS Guidelines for COVID-19 Management

One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the context of the COVID-19 pandemic.

Read more HERE

02- Procedural Rescheduling Criteria in the Pandemic Era

Patients with structural heart disease are at higher risk in the face of the new coronavirus infection due to both advanced age and numerous comorbidities.

Read more HERE

03- Cardiology in Times of Coronavirus: The Perfect Storm

Since January 2020, the COVID-19 infection has spread from China to the rest of the world. The clinical picture has several points in common with influenza, being mild or asymptomatic in most cases. However, around 15% of cases shows complications with interstitial pneumonia that can lead to respiratory failure.

Read more HERE

04- ST-Segment Elevation Myocardial Infarction in the Time of COVID-19

This study cites the experience of 6 sites during the first month of the COVID-19 pandemic in New York. All patients included had a confirmed diagnosis of coronavirus infection and also ST-segment elevation on electrocardiography.

Read more HERE

05- Interview with Dr. Gustavo Pedernera, New Director of the SOLACI Educational Newsletter

The SOLACI Educational Newsletter has a new director! It is Dr. Gustavo Pedernera, a prestigious clinical and interventional cardiologist, specialized in endovascular treatments at the Buenos Aires Cardiovascular Institute (Instituto Cardiovascular de Buenos Aires, ICBA), Argentina.

Read more HERE

06- Predilation in TAVR: Definitive Data for Easier Decision-Making?

Direct implantation (without predilation) resulted non-inferior vs. the conventional strategy with prior balloon aortic valvuloplasty using the S3 prosthesis (even though this did not translate into a simplified procedure). In a few patients, the prosthesis was not able to cross the native valve, which resulted in device retrieval and subsequent valvuloplasty. According to these data, direct implantation is possible if patients are selected correctly and providing you did not expect any benefits out of it. 

Read more HERE

07- Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS).

Read more HERE

08- A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it shows a favorable safety profile in populations with multiple comorbidities. 

Read more HERE

09- SURTAVI Follow-Up Completed with Good News

The assessment of all severe aortic stenosis patients at intermediate risk of the SURTAVI was finally completed, confirming inferiority against the traditional surgical replacement (SAVR) in hard points such as all-cause mortality and disabling stroke. 

Read more HERE

10- Reperfusion in the Time of COVID-19. What Has Changed?

We are living a pandemic due to the new COVID-19, but the world was already in the midst of a pandemic of cardiovascular disease. Both challenges defy healthcare systems worldwide, and the worst part is that they can coexist.

Read more HERE

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.